Attending Physician
Hospital Clínico Universitario de Santiago de Compostela, Spain
Disclosure(s): Gilead: Honoraria; Janssen: Advisor/Consultant; MSD: Honoraria; ViiV: Board Member
Antonio Antela was born in Las Palmas (Canary Islands, Spain) in 1960. He achieved his Medical Doctor degree in 1983 and the Internal Medicine specialty in 1989, both at the University of Santiago de Compostela, Spain. Between 1989 and 1991 he was a Fellow in Infectious Diseases in the Ramón y Cajal Hospital, in Madrid, Spain, and from 1991 to 2006 he worked continuously as an Attending Physician in the HIV Unit of the Infectious Disease Department of Ramón y Cajal Hospital. He obtained his PhD degree in 1999. He moved in 2006 to the Infectious Diseases Department of the University Hospital of Santiago de Compostela, where he continues his clinical and research work in the Infectious Diseases and HIV fields. Since 2013 he is also Professor of Infectious Diseases in the University of Santiago de Compostela.
He has been author of 191 articles in peer-reviewed international medical journals and more than 100 book chapters, and Principal Investigator of more than 120 clinical trials. He has worked in the AIDS Program of the Panamerican Health Organization (PAHO), in Washington, DC, USA, in 2003, and in the NGO Vihda’s AIDS Clinic in Maragwa (Kenya), in 2004. He has been Directive of Spanish AIDS Study Group (GeSIDA) in 1998-2002, Vice-President of the Spanish Interdisciplinary AIDS Society (SEISIDA), in 2004-2010, Directive of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), in 2015-2019, and co-author of the official Spain´s Antiretroviral Therapy Guidelines since 1998, and the officla Pre-exposure Prophylaxis of HIV infection Guidelines for Spain, in 2016 and in 2023.
His principal field of interest is HIV infection, in general, and antiretroviral therapy, in particular. He has been also involved in European working groups on the topics of adherence to antiretroviral therapy, access to HIV diagnosis and care, and initial antiretroviral therapy.